



**NUMERAL LTD**

**(formerly Go Life International Ltd)**

(Incorporated in the Republic of Mauritius)

(Registration number: 098177 C1/GBL)

Primary Listing SEM share code: GOLI.N0000

Secondary Listing JSE share code: XII

ISIN: MU0330N00004

("the Company" or "the Group" or "Numeral")

---

## UNAUDITED FINANCIAL RESULTS FOR THE NINE MONTHS ENDED 30 NOVEMBER 2024

---

### DIRECTORS' COMMENTARY

#### BACKGROUND

The Company was incorporated on 1 October 2010 as a public company limited by shares under the Mauritian Companies Act and holds a Global Business Licence (Licence No - C110009034) issued by the Mauritius Financial Services Commission. Numeral is registered in the Republic of Mauritius and was listed on the Stock Exchange of Mauritius ("SEM") on 7 July 2011. The Company completed a secondary listing on the Alternative Exchange ("AltX") of the JSE Limited ("the JSE") on 23 November 2016.

During 2023 the Company secured new funds and shareholders, who assisted with the process of regularising and repositioning the Company. The Company changed its name with effect from 15 December 2023 from Go Life International Ltd to Numeral Ltd.

The Company has been through some tough times over the last few years, but since the recapitalisation and the appointment of new board members, Company Secretary, Management Company and Registry Services, the Company had started to widen the scope of its current investment focus, being healthcare and biotechnology, to include financial services.

During 2024, the Board started pursuing the recovery of assets that the former Go Life International Ltd lost control over in the field of cryogenics, which efforts proved successful during the period under review. Furthermore, the financial reporting was brought up to date, the bank account revived and the Company completed its restructuring and regularising process and is now rebuilding the business, earning its first revenue during 2024 and returning to a profitable position. The main focus of the group remains health and biotechnology, although it is expected that the group will diversify over time.

#### ACQUISITIONS AND DISPOSALS

The Company acquired a new South African subsidiary, called Numeral Financial Services Proprietary Limited ("Numeral SA"), with an effective date of 1 March 2024, at no cost to the Company. This subsidiary was profitable in its first months of operation. However operations were halted to establish whether additional approvals will be required from the Mauritian authorities around financial services.

Numeral SA has been recognised as an official Google Partner. The main shareholders of the Company have deployed much time and effort into building the Numeral brand through the various digital platforms, and the success of these campaigns has been rewarded by Google through the recognition of the official partnership. This makes Numeral SA the 210<sup>th</sup> company in South Africa to be awarded with this prestigious accolade.

The Company also established Numeral Biotechnologies Proprietary Limited in South Africa, as a 100% owned subsidiary. Biotechnology remains a key focus of the Group and the Board is actively pursuing acquisitions and further investment in this sector.

### **Cryo-Save South Africa (Pty) Ltd**

During the period under review, the company was able to recover a 50% interest in Cryo-Save South Africa (Pty) Ltd ("Cryo-Save") as detailed in the Company's announcement dated 18 December 2020 wherein the Company (formerly known as Go Life) advised that it had added Cryo-Save to its group of companies in a joint venture with Esperite NV. Cryo-Save promotes the adoption of personalised and regenerative medicine among South Africans to improve their quality of life.

The former acquisition of Cryo-Save fell within the Company's strategy of being on the cutting edge of medical technology and this remains the case, however, with renewed focus on the full biotechnology vertical.

The Board is pleased to advise that it recently managed to recover 50% of Cryo-Save on behalf of Numeral, which has been returned to the Group for no consideration. The date of effective management control, following the recovery, was 1 September 2024. The Company will present consolidated financial results, including CryoSave, for the year ending 28 February 2025.

### **Other nutraceutical and Biotech investments**

The Company is making meaningful progress in continuing in its efforts to rebuild and grow the Group on the Biotechnology and Health segment, both organically and by way of acquisition, and will be leveraging its investment in Cryo-Save as a core upstream anchor asset in the biotech and stem-tech vertical, servicing downstream brands with their laboratory, stem-cell, stem-cell derivative and allied processing requirements.

There were no other acquisitions or disposals during the period under review.

Shareholders are also referred to Subsequent Events below

### **RELATED PARTIES**

There were no transactions with related parties during the period under review that are material to an understanding of these results.

### **BASIS OF PREPARATION**

These unaudited consolidated group results are prepared in accordance with International Financial Reporting Standards (IFRS<sup>®</sup>), IAS 34: Interim Reports, the SEM Listings Rules and the Listings Requirements.

The accounting policies adopted in the preparation of the condensed consolidated interim financial statements are in terms of IFRS and are consistent with those applied in the preparation of the annual financial statements as at and for the year ended 29 February 2024. These results have been prepared for the Board by Ms Anneri van der Merwe AGA(SA) – VAS Virtue Accounting Services.

### **SEGMENTAL ANALYSIS**

There are no separate segments on which to report with all operations currently being conducted in South Africa.

### **SUBSEQUENT EVENTS**

The company announced recently that it had agreed terms to acquire an effective 51% shareholding in Longevity Lab Proprietary Limited -('Longevity'). Numeral and Longevity have signed terms for Numeral to acquire an effective 51% of Longevity through an issue of ordinary shares in Longevity for cash ('the Transaction').

Longevity is a biotechnology business specialising in creating and managing discerningly appointed, world class wellness clinics and holistic wellness programs that incorporate nurse and doctor administered, leading stem cell and cellular optimisation medical treatments, through intravenous therapy protocols aimed at cellular detoxification, reduction in overall body inflammation and optimization of cellular health. Treatment packages include, inter alia, glutathione, vitamin drips, NAD drips, PRP treatments, stem cell treatments, health plans and health mentorship.

The acquisition is aligned with Numeral's strategy of building a fully vertically integrated biotechnology group, which will remain a key focus for the Numeral Board.

The transaction is subject to successful conclusion of the following conditions precedent:

- Relevant regulatory approvals, to the extent required;
- Signature of the full suite of transaction agreements;
- Due diligence to the satisfaction of the Numeral board; and
- Resolutions by the boards of both Parties approving the Transaction.

The Transaction falls outside of the Disclosable Transaction threshold of the SEM Listings Rules.

## PROSPECTS

Numeral is dedicated to regrowing its healthcare and biotech business as well as embracing technological and commercial opportunities in the vertical. It will also seek to diversify the Group through strategic acquisitions and pursuing new distribution channels through innovative platforms and strategic partnerships.

At the stage when a strategic acquisition is undertaken, in meeting the requirements, the Company will issue a listing circular, incorporating revised listing particulars, in accordance with the SEM Listings Rules and the JSE Listings Requirements. The information regarding the prospects of the Company included in this paragraph, including any forward-looking information, was not audited or reviewed by the Company's auditors.

## GOING CONCERN

The Group has started to show profits and retains the ongoing support of key shareholders.

## DIVIDEND

No dividends were authorised or paid during the period under review.

## DIRECTORS

There were no changes to the Board of Directors during the period under review:

## QUARTERLY INFORMATION

The Company is required to publish quarterly financial results in terms of the Listing Rule 12.19 of the SEM. The abridged unaudited quarterly financial statements ("QFS") have been prepared in accordance with the measurement and recognition requirements of International Financial Reporting Standards ("IFRS"), the requirements of IAS 34: Interim Financial Reporting and the SEM Listing Rules and the JSE Listings Requirements.

### STATEMENT OF FINANCIAL POSITION – UNAUDITED QUARTERLY INFORMATION

	Unaudited	Audited	Unaudited
USD	30 November	29 February	30 November
	2024	2024	2023
<b>ASSETS</b>			
<b>Current Assets</b>	<b>1,077,325</b>	<b>32,303</b>	<b>303</b>
Trade and other receivables	943,717	32,000	-
Cash and Cash Equivalents	133,608	303	303
<b>TOTAL ASSETS</b>	<b>1,077,325</b>	<b>32,303</b>	<b>303</b>
<b>EQUITY</b>			
<b>Capital and Reserves</b>	<b>204,575</b>	<b>(146,965)</b>	<b>(249,423)</b>
Share Capital	28,460,357	28,460,357	28,460,357
Accumulated Loss	(28,255,782)	(28,607,322)	(28,709,780)
<b>LIABILITIES</b>			
<b>Non current Liabilities</b>	<b>395,282</b>	-	-
Other Financial Liabilities	395,282	-	-

<b>Current Liabilities</b>	<b>477,468</b>	<b>179,268</b>	<b>249,726</b>
Loans from shareholders	256,823	77,808	82,892
Trade and other Payables	78,711	75,610	89,431
Loans from other related parties	141,934	25,849	77,403
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>1,077,325</b>	<b>32,303</b>	<b>303</b>

#### STATEMENT OF EARNINGS AND OTHER COMPREHENSIVE INCOME – UNAUDITED QUARTERLY INFORMATION

	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
USD	9 months to 30 November 2024	9 months to 30 November 2023	6 months to 31 August 2024	6 months to 31 August 2023	3 months to 31 May 2024	3 months to 31 May 2023	Year ended 29 February 2024
Revenue	449,337	-	188,973	-	9,995	-	83,184
Cost of Sales	-	-	-	-	-	-	-
Other Income	-	-	-	-	-	-	-
Expenses	(38,438)	(80,844)	(66,771)	(62,442)	(8,327)	(19,447)	(61,569)
<b>Operating profit/(loss) from operations</b>	<b>410,899</b>	<b>(80,844)</b>	<b>122,202</b>	<b>(62,442)</b>	<b>1,668</b>	<b>(19,447)</b>	<b>21,614</b>
Finance income	-	-	-	-	-	-	-
Finance costs	(59,360)	-	-	-	-	-	-
<b>Profit/(Loss) before taxation</b>	<b>351,539</b>	<b>(80,844)</b>	<b>122,202</b>	<b>(62,442)</b>	<b>1,668</b>	<b>(19,447)</b>	<b>21,614</b>
Taxation	-	-	-	-	-	-	-
<b>Net profit/(loss) after taxation</b>	<b>351,539</b>	<b>(80,844)</b>	<b>122,202</b>	<b>(62,442)</b>	<b>1,668</b>	<b>(19,447)</b>	<b>21,614</b>
Other Comprehensive income	-	-	-	-	-	-	-
<b>Total comprehensive profit/loss for the period</b>	<b>351,539</b>	<b>(80,844)</b>	<b>122,202</b>	<b>(62,442)</b>	<b>1,668</b>	<b>(19,447)</b>	<b>21,614</b>

#### STATEMENT OF CASH FLOWS – UNAUDITED QUARTERLY INFORMATION

	Unaudited 30 November 2024	Unaudited 30 November 2023	Audited 29 February 2024
<b>Cash flows from operating activities</b>			
Cash from/(used in) operations	<b>(557,077)</b>	-	<b>(16,415)</b>
<b>Cash flows from financing activities</b>			
Proceeds on issue of share capital	-	-	251,898
Advances of loans from group companies	116,085	-	(183,061)
Repayments of financial liabilities at fair value	574,297	-	(52,422)
<b>Net cash from financing activities</b>	<b>690,382</b>	-	<b>16,415</b>
<b>Net cash flow for period under review</b>	<b>133,305</b>	-	-
Cash and cash equivalents at the beginning of the period	303	303	303
<b>Cash and cash equivalents at the end of the period</b>	<b>133,608</b>	<b>303</b>	<b>303</b>

## STATEMENT OF CHANGES IN EQUITY

Figures in US Dollar	Share Capital	Share Premium	Total Share Capital	Accumulated Profit / (Loss)	Total Equity
<b>Balance at 01 March 2023</b>	<b>7,675,000</b>	<b>20,533,459</b>	<b>28,208,459</b>	<b>(28,628,937)</b>	<b>(420,478)</b>
Profit for the year	-	-	-	21,615	21,615
Other comprehensive income	-	-	-	-	-
<b>Total comprehensive income for the year</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>21,615</b>	<b>21,615</b>
Issue of shares	251,898	-	251,898	-	251,898
<b>Total contributions by and distributions to owners of company recognised directly in equity</b>	<b>251,898</b>	<b>-</b>	<b>251,898</b>	<b>-</b>	<b>251,898</b>
<b>Balance at 29 February 2024</b>	<b>7,926,898</b>	<b>20,533,459</b>	<b>28,460,357</b>	<b>(28,607,322)</b>	<b>(146,965)</b>
Profit for the 9 months ended 30 November 2024	-	-	-	351,539	351,539
Other comprehensive income	-	-	-	-	-
<b>Total comprehensive income for the period</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>351,539</b>	<b>351,539</b>
<b>Balance at 30 November 2024</b>	<b>7,926,898</b>	<b>20,533,459</b>	<b>28,460,357</b>	<b>(28,255,782)</b>	<b>204,575</b>

## RECONCILIATION OF BASIC EARNINGS TO HEADLINE EARNINGS

USD	Unaudited 9 months 30 November 2024	Unaudited 9 months 30 November 2023
Basic earnings/(loss)	351,539	(80,844)
Headline earnings/(loss) per share (USD cents)	351,539	(80,844)
Weighted average number of shares (net of treasury shares)	1,242,500,000	1,159,600,296
Basic and diluted (earnings)/loss per share (USD cents)	0.0283	(0.0070)
Headline earnings/(loss) per share (USD cents)	0.0283	(0.0070)

## AVAILABLE INFORMATION

Copies of the audited Annual Financial Statements for the year ended 28 February 2024 and the abridged unaudited interim and quarterly QFS and the statement of direct and indirect interests of each officer of the Company, pursuant to Rule 8(2)(m) of the Securities (Disclosure Obligations of Reporting Issuers) Rules 2007, are available free of charge, upon request to the at the registered office of the Company at 142 Mosque Road, Midlands, Mauritius.

This communiqué is issued pursuant to SEM Listing Rules 11.3, 12.14 and 12.20 and section 88 of the Securities Act of Mauritius 2005 as well as the JSE Listings Requirements. The Board accepts full responsibility for the accuracy of the information contained in these Financial Statements. The Directors are not aware of any matters or circumstances arising subsequent to the period ended 30 November 2024 that require any additional disclosure or adjustment to the Financial Statements.

Numeral has its primary listing on the Stock Exchange Mauritius and a secondary listing on the Alternative Exchange of the JSE Limited.

*This notice is issued pursuant to SEM Listing Rule 11.3 and the Mauritian Securities Act 2005. The Board of Directors of Numeral accepts full responsibility for the accuracy of the information contained in this announcement.*

**For and on behalf of the Board  
Mauritius**

17 January 2025

<b>Executive Directors:</b> Dave van Niekerk Neville Graham	<b>Non-Executive Directors:</b> Mohamed Yusuf Sooklall Dr Aansa Devi Bedacee
<b>JSE Sponsor:</b> AcaciaCap Advisors Proprietary Limited	<b>Management Company and Company Secretary:</b> LTS Management Services Limited